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Current Status and Future Diagnostic Trends of
Prenatal Illicit Drug Exposure in the NeonateWith regards to opiate abuse, heroin has become the most
common illicit drug in Taiwan. In pregnant women, opiate
abuse contributes to adverse effects, such as low birth body
weight, premature delivery, and life-long developmental
consequences in the neonate.1 Clinical characteristics for
opiate or poly-drug exposure in utero, resulted in neonatal
withdrawal syndrome, which required clinical observation
and treatment for days or even weeks in hospital. The
American Academy of Pediatrics published guidelines
which include the monitoring and treatment of neonatal
abstinence syndrome (NAS) following in utero opiate or
poly-drug exposure. Among these patients, NAS was the
most observed clinical finding, and included dysfunction of
the central nervous system, autonomic nervous system,
gastrointestinal tract, and respiratory system.1 In some
severe cases, NAS led to deleterious outcomes, such as
diarrhea, fever, seizure, feeding intolerance, poor weight
gain and even death. Moreover, poly-drug abusers, who
used multiple illicit substances during pregnancy, declined;
this obscured the clinical situation with regards to the
treatment of their offspring.2 Thus, the identification of
illicit drugs, while the patient suffers during the perinatal
period, could provide an imperative basis for clinical diag-
nosis and potential management. Practically speaking, this
identification should be assessed in both mothers and their
newborn. Samples used in newborn drug testing included
urine, meconium, hair, and umbilical cord segment. Urine
testing of the neonate for illicit drugs, revealed a low bio-
logical sensitivity, as this procedure can only detect recent
drug exposure. In addition, since the earliest collection of
the newborn’s urine with the highest concentration of an
analyzed substance was often missed, due to practical
clinical difficulties, meconium drug testing was more bio-
logically sensitive and easier to perform.3 However, meco-
nium passage in a newborn may take several days; this
often delayed the clinical diagnosis. Su et al4 measured
hairs of neonates; this method was potentially more bio-
logically sensitive and more rapid in the identification of
poly-drug use. Indeed, it has been reported that hair
analysis was costly and good at detecting chronic exposure,1875-9572/$36 Copyright ª 2012, Taiwan Pediatric Association. Publish
doi:10.1016/j.pedneo.2012.01.003but, although it exerted a high biological sensitivity for
opiate, amphetamine, and cocaine, it showed a low bio-
logical sensitivity for marijuana exposure.5 In addition, hair
analysis provided a possible duration of illicit drug expo-
sure, by the measurement of the hair segment. Although
this technique is not widely available at present, it is
a potential survey tool for use in important aspects of
clinical needs. It is worth considering for unsolved issues
underlying illicit drug exposure in the neonate prenatally,
such as the occurrence and severity of NAS, and neonatal
psychomotor behavior after poly-drug exposure.
Treatment of prenatal substance use or abuse should be
started before delivery. Since the 1970s, methadone,
a synthetic opiate, has been recommended for opioid
dependence in pregnant women, to improve maternal
health and neonatal outcomes, such as lower birth weight
and NAS.6 Buprenorphine, a partial agonist of the mu-opioid
receptor and a partial antagonist of the kappa-opioid
receptor, was first introduced in 1996 and is increasingly
being used for opioid addiction treatment, due to fewer
autonomic side effects, in non-pregnant women. Bupre-
norphine was also thought to be a better treatment for
opioid abuse in pregnant women, due to the need for less
morphine, shorter duration of treatment for NAS, and
a shorter hospital stay of neonates with perinatal morphine
exposure.7 The reason for the high attrition rate remains to
be addressed in future research. Prospectively, there will
be a trend to use buprenorphine as the first line medication
for opioid dependence in pregnant women. Therefore, hair
analysis in neonates for in utero illicit drug exposure should
include buprenorphine as a future candidate.
The prevalence of illicit drug abuse has increased in
pregnant and non-pregnant women recently. Although
current medical technology and environment can provide
a better treatment, decreasing drug abuse in pregnant
women is more efficient. Thus, more attention and studies
should be focused on a rapidly, widely available, cheap,
and accurate survey for neonates with prenatal poly-drug
exposure, in order to develop a suitable clinical and ther-
apeutic strategy.ed by Elsevier Taiwan LLC. All rights reserved.
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